Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by a persistent inflammatory and remodelling response of the airways causing respiratory symptoms, progressive decline besides in lung function, respiratory failure, cor pulmonale and death \[[@CR1]--[@CR7]\]. COPD is estimated to become the third leading cause of death in 2030 ([www.who.int/whosis/whostat/2008/en/](http://www.who.int/whosis/whostat/2008/en/)). As expected, COPD and the catastrophic complications of advanced stage disease impose a substantial economic burden on healthcare systems; in the US alone, direct costs of COPD have been estimated at \$29.5 billion, with indirect costs of \$20.4 billion \[[@CR8]\]. Studies in the UK have estimated an annual direct cost of treatment per patient of £819 \[[@CR9]\].

The distinctive inflammatory response of the airways in COPD is generally associated with tobacco smoking \[[@CR2], [@CR3]\], with about 15--20% of smokers developing a diagnosis of COPD \[[@CR4]\]. Furthermore, COPD smokers or ex-smokers are at an increased risk for lung cancer \[[@CR5]\], cardiovascular diseases \[[@CR6], [@CR7]\] and diabetes \[[@CR10]\].

Smoking cessation is the only evidence based strategy known to improve the COPD prognosis \[[@CR11], [@CR12]\]. Smoking cessation reduces the rate of annual decline in pulmonary function, attenuates respiratory symptoms of cough and sputum, and improves health status \[[@CR13]--[@CR15]\]. Additionally, stopping smoking reduces the risk of developing and eventually dying from lung cancer, cardiovascular disease and other tobacco-related illnesses \[[@CR16]\]. Therefore, it is important to recommend COPD patients who smoke to quit as early as possible.

Although FDA-approved smoking cessation drugs (i.e. nicotine replacement therapy, buproprion, and varenecline) in combination with counseling have been shown to promote abstinence in COPD patients who smoke, the relapse rate is very high compared to smokers in the general population \[[@CR17]\]. Unsuccessful smoking cessation and relapses are more frequently reported in COPD patients \[[@CR18], [@CR19]\], mainly because of their higher pack-year history, greater degree of nicotine dependence, inferior motivation to quit, and increased risk for depressive symptoms \[[@CR20]\]. Improved quit rates would be desirable in a population that generally responds poorly to smoking cessation efforts. Consequently, the need for novel and more efficient approaches to smoking cessation interventions is unquestionable.

Electronic cigarettes (ECs) are battery-operated devices designed to vaporise nicotine without burning tobacco. ECs are now regulated in the EU by the new Tobacco Products Directive (TPD) \[[@CR21]\], which mandates that e-vapour products are only placed on the market if the nicotine dose and uptake is reported and toxicological risk assessment is carried out on aerosol emissions. Marketing of ECs is now legal in the United States, where the FDA recently finalized rules for the regulation of ECs as a tobacco product ([www.who.int/whosis/whostat/2008/en/](http://www.who.int/whosis/whostat/2008/en/)).

These consumer products share many similarities with smoking in the behavioural aspect of their use \[[@CR22]\]. Users are predominantly smokers, who report using them long-term as an alternative to conventional cigarettes, reduce their consumption or quit smoking, alleviate tobacco withdrawal symptoms, and continue having a 'smoking' experience \[[@CR23]\], but mitigated health risks \[[@CR24], [@CR25]\]. Data from clinical trials \[[@CR26]--[@CR28]\] and meta-analyses \[[@CR29]\] have shown that ECs may help smokers quitting or reducing their tobacco consumption and their use is well tolerated. There is a lack of data on the health effects of EC use amongst smokers with COPD in the literature. In particular, the impact of inhaling aerosol emissions from ECs on routinely assessed objective and subjective respiratory outcomes in COPD patients is unknown. Here we report, a 24-month follow-up of respiratory outcomes in smokers with a diagnosis of COPD who quit or reduced substantially their tobacco consumption by switching to regular ECs use.

Methods {#Sec2}
=======

This retrospective study was conducted at four Italian hospitals over the period September 2013 to December 2015 in the outpatient setting. The study was approved by the ethics review board of the coordinating center ("Policlinico-Vittorio Emanuele Hospitals") and informed consent was obtained from each patient.

Patient population {#Sec3}
------------------

A review of the case notes of patients with COPD regularly followed up was conducted. Patients reporting regular daily use of ECs (and if at all conventional cigarettes) at least two follow-up visits over a 24-months period were eligible to for inclusion. A second group of age- and sex-matched COPD patients reporting to be regular smokers (and not using ECs) over the same observation period was selected from the four participating clinics as reference (control) group.

The diagnosis of COPD was made according to the Global initiative for Chronic Obstructive Lung Disease (GOLD) criteria \[[@CR1]\]. In particular, selected patients had to have a ≥30 pack year smoking history and an obstructive post-bronchodilator spirometry ratio (i.e. \<70%) documented in their notes. Smokers with COPD followed-up at these outpatient clinics were regularly asked about their smoking behaviour and given brief advice about quitting smoking. If interested in being assisted in a quit attempt they were referred to the smoking cessation clinic.

Study design {#Sec4}
------------

A physicians from each of the participating centres reviewed the clinical notes of patients attending the clinics. COPD patient data was extracted from the clinic visit immediately preceding \[baseline visit\] the first of the two follow-ups visits \[follow-up visit 1 and 2\]. In brief, data from the three clinic visits were collected and analysed. Follow-up visits 1 (F/up1) and 2 (F/up2) were carried out at 12 (±1.5) and 24 (±2.5) months after baseline visits, respectively.

Study outcomes assessed {#Sec5}
-----------------------

The primary outcomes of interest were: a) reduction in cig/day consumption; and b) number of exacerbations in the previous 12 months at each of the visits and how they may have changed over the 24-month period in the EC group compared to the control group. Secondary outcomes of interest were changes from baseline to the final follow-up visit in: a) lung function; b) COPD Assessment Test (CAT) scores; and c) 6-min walk distance (6MWD). In addition, changes in the relative proportion of COPD GOLD stages throughout the 24-months observation period were reported for both study groups as well as the change in mean FEV1 from baseline to F/up2.

Study assessments {#Sec6}
-----------------

At each routine outpatient clinic visit, patients were assessed using a standard approach consisting of review of smoking history, respiratory ailments and exacerbations, clinical examination, vital signs (blood pressure, heart rate, body weight), post-bronchodilator spirometry and GOLD staging \[[@CR1]\], completion of the CAT ([www.CATestonline.org](http://www.catestonline.org/)) and re-evaluation of treatment adherence and efficacy. The CAT is a validated, short (8-item) and simple patient-completed questionnaire developed for use in routine clinical practice to assess health status of patients with COPD \[[@CR30]\]. A change of 2 units is considered to be the minimal clinical importance difference \[[@CR31]\]. If deemed appropriate and amenable, a 6MWD test was conducted to measure the overall ability to perform daily physical activities \[[@CR32]\].

For the purposes of the study, severe exacerbations were defined as those requiring a course of antibiotics and/or oral corticosteroids via their primary care physician, attendance to the emergency department for nebulisation and/or hospital admission for their respiratory symptoms with the requirement of antibiotics and oral corticosteroids. Spirometry was conducted post-bronchodilator for measurement of forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), and the expiratory ratio computed as percentage (%FEV1/FVC).

Patients' data at the outpatient visits were extracted from their medical record and entered into an electronic spreadsheet for statistical computation.

Analyses {#Sec7}
========

Parametric data were expressed as mean (±standard deviation (SD)) while non-parametric data expressed as median (interquartile range (IQR)). We also delineated data for single (exclusive ECs use) and '*dual users*' (i.e. ECs users who also smoke conventional cigarettes). Statistical comparisons of parameters were assessed using student's *T*-test and Wilcoxon-signed rank test depending on whether the data was parametric or not, respectively. Similar statistical analyses were conducted on dual and single users within groups from baseline. Missing measurements were not included in the analyses. With the study involving repeated parameter measurements, analysis of repeated measures with Bonferroni correction was conducted for between groups over the study period. A two-tailed p value of less than 0.05 was considered to indicate statistical significance. All analyses were performed with the Statistical Package for Social Science (SPSS for windows version 18.0, Chicago, IL, USA).

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

Data from a total of 48 COPD patients were included in the study. Patients had mild to very severe disease according to the GOLD criteria and were treated accordingly \[[@CR1]\]. Twenty-four patients with COPD reporting regular daily EC use on two follow-up visits over the observation period of 24-months and twenty-four COPD matched controls were identified. Baseline demographic, COPD GOLD stage, objective and subjective parameter data on both study groups are summarised on Table [1](#Tab1){ref-type="table"}. There were no significant differences in the measured parameters at baseline.Table 1Baseline demographics of the subjects on the studyCOPD ControlsCOPD E-Cig usersBaseline *P*-value between groupsAge^c^65.3 (±5.5)66.9 (±6.7)0.350Sex21 M, 3 F20 M, 4 F-COPD GOLD stage Stage 132- Stage 256- Stage 31110- Stage 456-post-BD FEV1^b^ (L)1.47 (1.13, 1.72)1.25 (0.94, 1.78)0.298post-BD FVC^b^ (L)2.39 (2.1, 2.64)2.37 (2, 2.65)0.902%FEV1/FVC^c^56.2 (±10.3)59.4 (±8.4)0.244Pack years of smoking^c^51.7 (±9.9)52.4 (±10.7)0.365Cig/day^c^20.5 (±3.3)21.8 (±4.4)0.228CAT score^b^20.5 (17.8, 24.3)21.5 (17.8, 25.3)0.710COPD Exacerbations^a,\ c^2.1 (±1.1)2.3 (±1)0.440Co-morbidities Respiratory failure56 CHF33 CHD23 Hypertension98 Diabetes45 OSAS63 Chronic Kidney Failure10 Liver cirrhosis10 Lung cancer01 Pulmonary hypertension01 GERD32 Degenerative joint disease24 Osteoporosis21 Depression/Anxiety24*Abbreviations*: *COPD* Chronic obstructive pulmonary disease, *M* male, *F* female, *BD* bronchodilator, *L* litre, *FEV1* forced expiratory volume in 1 s, *FVC* forced vital capacity, *Cig* conventional cigarettes, *CAT* COPD assessment tool, *CHF* chronic heart failure, *CHD* coronary heart disease, *OSAS* obstructive sleep apnoea syndrome, *GERD* Gastroesophageal reflux disease^a^ COPD exacerbations in past 12 months^b^ Median (interquartile range); ^c^ Mean (± standard deviation)

Changes in smoking behaviour and patterns of EC use {#Sec10}
---------------------------------------------------

Patients' cigarettes consumption at baseline and at follow-up visits are illustrated in Fig. [1](#Fig1){ref-type="fig"}. A substantial reduction in conventional cigarette consumption was observed in COPD EC users, their mean (±SD) cigarettes/day use decreasing from 21.8 (±4.4) at baseline to 1.8 (±2.2) at F/up1 and to 1.58 (±2.0) at F/up2, respectively (*p* \< 0.001 for both visits) (Table [2](#Tab2){ref-type="table"}). As expected, no significant change in conventional cigarette consumption was observed in the reference group.Fig. 1Changes in the number of cigarettes smoked in a day from baseline, at follow-up visit 1 (12 ± 1.5 months) and visit 2 (24 ± 2.5 months) separately for electronic cigarettes users (*closed circles*) and controls (*closed triangles*). All data expressed as mean and error bars are standard deviation of the mean. The p value is an overall comparison of both groups over the 24-month period Table 2Comparison of controls and e-Cigarette users at baseline, 12-month and 24-month follow-up visitsBaseline12-Month Follow-upWithin group p value vs Baseline^Ω^24-Month Follow-upWithin group *P* value vs Baseline^Ω^Overall between group *p* value from Baseline^ƙ^COPD Controls (*n* = 24) post-BD FEV1^a^ (L)1.47 (1.13, 1.72)1.43 (1.12, 172)0.5381.45 (1.17, 1.66)0.6570.223 post-BD FVC^a^ (L)2.39 (2.1, 2.64)2.35 (2.2, 2.74)0.0652.35 (2.19, 2.83)0.1410.977 %FEV1/FVC^b^56.2 (±10.3)55.9 (±10.1)0.32856.3 (±10.1)0.2770.033 Cig/day^b^20.5 (±3.3)20.1 (±3.7)0.37119.8 (±5)0.296\<0.001 CAT score^a^20.5 (17.8, 24.3)20 (17.5, 24.3)0.07520 (15.8, 24)0.3610.001 COPD Exacerbations^b^2.1 (±1.1)2.2 (±1)0.9062.1 (±1.1)0.8190.005 6MWD^a,\ c^267.3 (195, 351.5)270 (210.3, 372)0.056270.5 (220.8, 373.9)0.0960.002COPD EC users (*n* = 24) post-BD FEV1^a^ (L)1.25 (0.94, 1.78)1.23 (0.93, 1.73)0.1021.29 (0.92, 1.67)0.153 post-BD FVC^a^ (L)2.37 (2, 2.65)2.45 (1.92, 2.73)0.0812.46 (1.84, 2.86)0.252 %FEV1/FVC^b^59.4 (±8.4)58.3 (±8.6)0.45757.9 (±8.5)0.483 Cig/day^b^21.8 (±4.4)1.8 (±2.2)\<0.0011.58 (±2)\<0.001 CAT score^a^21.5 (17.8, 25.3)17.5 (15.8, 20.5)\<0.00118 (15, 20)\<0.001 COPD Exacerbations^b^2.3 (±1)1.8 (±1)0.0021.4 (±0.9)\<0.001 6MWD^a,\ c^266.5 (187.5, 313.5)307 (219.5, 342)0.002327 (239.5, 359.5)0.002*Abbreviations*: *COPD* Chronic obstructive pulmonary disease, *EC* e-Cigarette, *n* number, *BD* bronchodilator, *L* litre, *FEV1* forced expiratory volume in 1 s, *FVC* forced vital capacity, *Cig* conventional cigarettes, *CAT* COPD assessment tool, *6MWD* 6 min walk distance^a^ Median (interquartile range); ^b^ Mean (± standard deviation)^c^ 13 subjects in the COPD E-Cig user group and 14 in the COPD control group^Ω^ Statistical analyses conducted using Mann Whitney *U* Test (as data non-parametric) except for Cig/day and COPD exacerbations which were analysed using student *T* test (parametric data)^ƙ^ Statistical analyses conducted using repeated measures ANOVA with Bonferroni adjustment

Complete abstinence from tobacco smoking was observed in 13/24 (54.2%) of COPD EC users. Dual usage was reported by 11/24 (45.8%) COPD EC users. Nonetheless, a significant reduction in conventional cigarette consumption was also observed in dual users, with their mean (±SD) cigarettes/day use decreasing from 23.7 (±5.4) at baseline to 4 (±1.2) at F/up1 and to 3.5 (±1.3) at F/up2, respectively (*p* \< 0.001 for both visits) (Table [3](#Tab3){ref-type="table"}). More than 75% reduction from baseline in cigarette/day consumption was reported by all COPD EC dual users at both follow-up visits.Table 3Comparison of e-Cigarette and conventional cigarette users (dual users) vs e-Cigarette only users (single users) at 12- and 24-month follow-up visitsParameterBaseline12-Month Follow-up24-Month Follow-upCOPD EC users reducing cig use (dual users)(*n* = 11)(*n* = 11)(*n* = 11) Sex10 M, 1 F10 M, 1 F11 M % Smoking reduction compared to baseline-82.6 (±4.8)85.1 (±4.7) post-BD FEV1^a^ (L)1.23 (0.94, 1.6)1.20 (0.91, 1.70)1.28 (0.92, 1.96) post-BD FVC^a^ (L)2.34 (2.04, 2.86)2.35 (2.07, 2.89)2.57 (2.22, 2.93) %FEV/FVC^a^50.9 (47, 61.2)51.2 (46.9, 64)51.8 (43.3, 65.7) Cig/day^b^23.7 (±5.4)4 (±1.2)3.5 (±1.3) CAT score^a^25 (19.5, 26.5)20 (18, 22)18 (15, 22) COPD Exacerbations^b^2.6 (±0.8)2.3 (±0.8)1.5 (±0.8)COPD EC users ceasing cig use (single users)(*n* = 13)(*n* = 13)(*n* = 13) Sex10 M, 3 F10 M, 3 F9 M, 3 F Smoking reduction compared to baseline\-\-- post-BD FEV1^a^ (L)1.32 (0.96, 1.76)1.26 (0.94, 1.72)1.3 (0.95, 1.63) post-BD FVC^a^ (L)2.57 (2.01, 2.65)2.57 (1.92, 2.72)2.44 (1.72, 2.82) %FEV/FVC^a^61.9 (50.8, 66.4)61.5 (50.6, 65.6)61.5 (50, 65.2) Cig/day^b^20.2 (±2.7)\-- CAT score^a^20 (17, 24)16 (14, 18)17 (15, 20) COPD Exacerbations^b^2.07 (±1.0)1.3 (±1)1.4 (±1)*Abbreviations*: *n* number, *COPD* Chronic obstructive pulmonary disease, *EC* e-Cigarette, *M* male, *F* female, *BD* bronchodilator, *L* litre, *FEV1* forced expiratory volume in 1 s, *FVC* forced vital capacity, *cig* conventional cigarettes, *CAT* COPD assessment tool^a^Median (interquartile range); ^b^ Mean (± standard deviation)

COPD exacerbations {#Sec11}
------------------

There was a significant reduction in annual COPD exacerbations within the COPD EC user group, their mean (±SD) decreasing from 2.3 (±1) at baseline to 1.8 (±1; *p* = 0.002) at F/up1 and to 1.4 (±0.9; *p* \< 0.001) at F/up2, while no significant change was observed in the control group (Table [2](#Tab2){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}). A between groups significant reduction (*p* = 0.005) in COPD exacerbations over the 24 months observation period was also noted (Table [2](#Tab2){ref-type="table"}).Fig. 2Changes in the number of COPD exacerbation from baseline, at follow-up visit 1 (12 ± 1.5 months) and visit 2 (24 ± 2.5 months) separately for electronic cigarettes users (*closed circles*) and controls (*closed triangles*). All data expressed as mean and error bars are standard deviation of the mean. The *p* value is an overall comparison of both groups over the 24-month period

A significant reduction in COPD exacerbations was also observed in dual users, but only at 24 months; the number of exacerbation were reduced from 2.6 (±0.8) at baseline to 1.5 (±0.8; *p* = 0.002) at F/up2 (Table [3](#Tab3){ref-type="table"}). In the single users there was marked reduction in exacerbations at F/up1 (*p* = 0.002) and F/up2 (*p* = 0.009) compared to baseline (Table [3](#Tab3){ref-type="table"}). Of note, none of the patients included had a significant modification in COPD medications during the observation period.

Lung function assessments and COPD staging {#Sec12}
------------------------------------------

Compared to baseline there were no significant differences in the post-bronchodilator FEV1, FVC and %FEV1/FVC between study groups (Table [2](#Tab2){ref-type="table"}; Fig. [3a, b and c](#Fig3){ref-type="fig"}). There were no overall within group differences in spirometric assessments over the 24 month study period. Nonetheless, there was a significant difference (*p* = 0.037) in the rate of FEV1 decline at the 24-month follow-up visit in COPD ECs users (mean increase 39 mls) than in the control group (mean decrease 12 mls).Fig. 3Changes in FEV1 (**a**), FVC (**b**), and %FEV1/FVC (**c**) from baseline, at follow-up visit 1 (12 ± 1.5 months) and visit 2 (24 ± 2.5 months) separately for electronic cigarettes users (*closed circles*) and controls (*closed triangles*). All data expressed as mean and error bars are standard deviation of the mean. The p value is an overall comparison of both groups over the 24-month period

GOLD COPD staging variations are illustrated on Fig. [4](#Fig4){ref-type="fig"}. Over the 24-months observation period, we noted that a few COPD patients in the EC study group downstaged from GOLD Stage 4 to GOLD Stage 3 and 2. In contrast, the relative proportion of COPD GOLD stages for the reference group was virtually unchanged during the course of the study.Fig. 4Bar chart representing COPD GOLD stage changes over the study period. NB: Twenty-four patients in each group

CAT scores and 6MWD {#Sec13}
-------------------

COPD symptoms, as assessed using the CAT, at both follow-up visits decreased statistically (both F/up1 and F/up2 *p* \< 0.001) and clinically significantly (follow-up visit 1 and 2 reductions of 4 and 3.5 units, respectively) in the EC group, whereas there was little change in the control group (Table [2](#Tab2){ref-type="table"}; Fig. [5](#Fig5){ref-type="fig"}). Similar overall between group significantly statistical improvements (*p* = 0.001) were noted in favour of the EC user group.Fig. 5Changes in COPD Assessment Test (CAT) scores from baseline, at follow-up visit 1 (12 ± 1.5 months) and visit 2 (24 ± 2.5 months) separately for electronic cigarettes users (*closed circles*) and controls (*closed triangles*). All data expressed as mean and error bars are standard deviation of the mean. The p value is an overall comparison of both groups over the 24-month period

Results of 6MWD were only available in 13 patients of the EC user group and 14 of the control group (Table [2](#Tab2){ref-type="table"}; Fig. [6](#Fig6){ref-type="fig"}). Over the 24 months observation period, the median 6MWD improved more than 60 m (*p* = 0.002) in the EC user group compared to just over a median of 3 m (*p* = 0.096) in the control group. Significant overall between group improvements were also noted in favour of the EC user group.Fig. 6Changes in the 6-min walk distance (6MWD) test from baseline, at follow-up visit 1 (12 ± 1.5 months) and visit 2 (24 ± 2.5 months) separately for electronic cigarettes users (*closed circles*) and controls (*closed triangles*). All data expressed as mean and error bars are standard deviation of the mean. The p value is an overall comparison of both groups over the 24-month period

Discussion {#Sec14}
==========

No formal efficacy assessment of EC use has been conducted in patients with COPD. Here, we show for the first time, albeit retrospectively, that COPD patients were able to quit or substantially reduced their tobacco consumption by switching to regular ECs use. In these patients we also document an improvement in several objective and subjective respiratory outcomes; in particular COPD exacerbations, annual decline in FEV1, CAT scores and 6MWD. Quality of life and attenuation of disease exacerbations was reported in a COPD patient switching ot vaping in a case series of three inveterate smokers \[[@CR33]\]. A substantial reduction in conventional cigarette consumption was observed in COPD patients who switched to regular ECs use, with complete long-term abstinence from tobacco smoking being reported in over half of the COPD EC users. Dual usage was common (45.8%), though conventional cigarette consumption was substantially reduced, with all dual users smoking at least 75% less cigarettes compared to their baseline. Our observation of a 2-years abstinence rate of about 50% in a population, albeit small, that generally responds poorly to smoking cessation efforts is one of the highest ever reported in smoking cessation literature. The large magnitude of this effect in COPD may be explained by the fact that these products are known to replicate the smokers' smoking experience and associated rituals, the great compensatory effect of EC at both physical and behavioral level is likely to explain the observed high success rates \[[@CR22]\]. The same mechanism has been shown to drive key success rates among other vulnerable patients populations who switched to daily EC use, including asthma and schizophrenia \[[@CR34]--[@CR36]\].

Although smoking cessation is one of the few interventions shown to reduce all-cause mortality in patients with COPD \[[@CR37]\], there is limited data showing the benefits of smoking cessation in reducing exacerbations. Our study is the first to consider the number of COPD exacerbations as an outcome in a smoking cessation study. We observed that in COPD patients who have switched to regular ECs use, there was a significant reduction in COPD exacerbations in exclusive EC users as well as dual users. These preliminary findings are in agreement with the reduced risk of COPD exacerbations of two large population studies \[[@CR38], [@CR39]\]. Godtfredson et al. reported that previous smokers had a 43% lower risk of hospitalization for COPD compared with current smokers \[[@CR38]\]. Au et al. reported a 22% reduced risk of COPD exacerbations in ex-smokers compared with current smokers when adjusted for comorbidity, markers of COPD severity, and socioeconomic status \[[@CR39]\]. By contrast, in the Lung Health Study \[[@CR40]\] and in a 2.5-years follow up of 64 COPD patients by Kessler et al. \[[@CR41]\] there was no significant difference in the risk of hospital admission between current smokers and ex-smokers. However, these studies were not consistent in considering influential confounders for the risk of COPD exacerbations such as duration of smoking abstinence, COPD severity, comorbidities, age, etc. In our investigation the two study groups were evenly mached for all these confounders. The marked attenuation in COPD exacerbations may be explained by the cessation/reduction in chronic exposure of the airways to cigarette smoke which is known to promote susceptibility to infection through a number of different mechanisms \[[@CR42]--[@CR44]\]; and switching to ECs is likely to lower the risk of respiratory infections and pneumonia \[[@CR45]\]. Besides, regular vaping has been reported to favourably alter anti-microbial and -inflammatory activity in exhaled breath \[[@CR46]\] besides the theoretical benefit of propylene glycol in its aerosol form being a potent bactericidal agent.

We did not observe any significant change in the post-bronchodilator FEV1, FVC and %FEV1/FVC within study groups. The lack of significant changes in standard spirometric indices after smoking cessation is not unusual in smokers with COPD \[[@CR47], [@CR48]\], which may be due to the pathophysiology associated with COPD \[[@CR2], [@CR3]\] especially in more advanced disease. Importantly, this is not the case in asthmatics in studies of comparable design \[[@CR34], [@CR35]\].

The effect of smoking on the progressive decline in lung function in COPD is well established \[[@CR49]\] and attenuation in the annual rate of FEV1 decline has been generally reported in smoking cessation studies of COPD patients \[[@CR13], [@CR14]\]. In the current study, there was a significant reversal in the annual FEV1 decline at 24-month in COPD ECs users compared to COPD controls. Surprisingly, the improvement in the annual FEV1 decline was more so in the dual users than the single users; this was probably due to the higher proportion of less severe COPD GOLD stages in dual users.

Besides the observed reduction in exacerbation rates, amelioration of overall health status (as measured by CAT) and physical activity (measured by 6MWD) in the COPD patients who quit or reduced substantially their tobacco consumption by switching to regular ECs use are also novel and clinically relevant findings. Similar improvements in CAT scores and 6MWD have been shown in COPD patients undergoing intensive rehabilitation programs \[[@CR31], [@CR50]\]. The mechanism for these improved health outcomes following smoking cessation may be related to the substantial reduction in carbon monoxide (CO) (as well as in COHb levels) when giving up smoking \[[@CR46]\] and the related time-dependent improvement in exercise tolerance upon smoking abstinence \[[@CR51]\]. An internet based survey in COPD (*n* = 1190) and asthma (*n* = 1308) subjects has shown self-reported improved respiratory outcomes when switched to EC use of 75.7% and 65.4% respectively \[[@CR23]\]. Surprisingly, with the use of ECs about a fifth of the all the subjects in the survey ceased to use any of their respiratory drugs and only around 1% of the asthmatics and COPD subjects had worsening respiratory symptoms.

There are some limitations in our study. Firstly, this is a relatively small retrospective study, hence the results cannot be generalized and must be interpreted with caution. Despite the small number of subjects we noted significant results in several crucial study endpoints. Standard concerns associated with retrospective studies (including variance in the quality of information recorded by medical professionals and difficulty in establishing a causal relationship) also need consideration. Nonetheless, a clear advantage conducting this type of study is the generation of hypotheses that can be tested prospectively under controlled conditions. Secondly, it is possible that patients in this study represent a self-selected sample, which may not be representative of all COPD smokers who tried ECs. Furthermore, assessment of smoking abstinence was self-reported and liable to recall bias. However, self-reported number of cigarettes smoked per day in studies of this type is not subjected to the kind of biases observed in clinical trials where there is the tendency to claim abstinence \[[@CR52]\]. Moreover, similar beneficial effects were also reported in *dual users* (i.e., smoking reducers) and therefore objective measures of abstinence are unlikely to be of great importance. Additionally, the 6MWD was not conducted in all patients as it is not standard requirement and some patients declined.

Conclusions {#Sec15}
===========

Regular ECs use may help smokers with COPD attenuate conventional cigarette consumption or remain abstinent, as well as improve subjective and objective COPD outcomes. The potential role of the e-vapor category for smoking cessation and/or harm reduction in COPD requires confirmation from larger prospective studies. Nonetheless, the notion that substitution of conventional cigarettes with ECs is unlikely to raise significant health concerns in COPD is generally reassuring and should be communicated to patients with COPD using or intending to use ECs. Moreover, given that smoking cessation is a behavioural transition not a biomedical cure for a disease, the approach should rest on the informed choice of COPD smokers and their view of what they think might work for them with the physician as an adviser rather than prescriber.
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